Abstract:Xing Yan, 1 Shan Mei Liu, 2 Changhong Liu 1 1 The Second Affiliated Hospital of Dalian Medical University, Dalian, 116000, People's Republic of China; 2 Inner Mongolia Medical University, Hohhot, 150110, People's Republic of China Correspondence: Changhong Liu, The Second Affiliated Hospital of Dalian Medical University, Dalian, 116000, People's Republic of China, Tel +86 17709870870, Email As one of the first characteristics of cancer cells, chromosomal aberrations during cell division have been well documented. Aneuploidy is a feature of most cancer cells accompanied by an elevated rate of mis-segregation of chromosomes, called chromosome instability (CIN). Aneuploidy causes ongoing karyotypic changes that contribute to tumor heterogeneity, drug resistance, and treatment failure, which are considered predictors of poor prognosis. Lung cancer (LC) is the leading cause of cancer-related deaths worldwide, and its genome map shows extensive aneuploid changes. Elucidating the role of aneuploidy in the pathogenesis of LC will reveal information about the key factors of tumor occurrence and development, help to predict the prognosis of cancer, clarify tumor evolution, metastasis, and drug response, and may promote the development of precision oncology. In this review, we describe many possible causes of aneuploidy and provide evidence of the role of aneuploidy in the evolution of LC, providing a basis for future biological and clinical research. Keywords: aneuploidy, chromosome instability, mitosis, mutation, non-small cell lung cancer As one of the most common malignancies globally, non-small cell lung cancer (NSCLC) has a higher morbidity and a poorer prognosis. At present, the most common causes of death for lung cancer patients are recurrence and metastasis. 1 Therefore, it is important to explore the pathogenesis of NSCLC in order to find more effective treatment strategies. There are a number of efficient and specific biomarkers that can be used to diagnose, prognosis, and monitor the progression of NSCLC. In recent years, high-throughput sequencing of the whole genome of cancer patients correlate aneuploidy with cancer development and chromosomal instability. 2 Cancers with an unequal number of chromosomes (increase or loss of copy number), aneuploidy, have been observed for more than 100 years. Its functional effect is usually thought to be achieved through inhibition of tumor suppressor genes and overexpression of oncogenes. 3 In approximately 90% of cancer patients, the genomic sequence has undergone considerable changes which are closely related to clinical outcomes 4 Duesberg et al 5 put forward the "carcinogenicity theory of chromosome aneuploidy" 20 years ago, which indicated that aneuploidy was the key cause of genomic instability and tumorigenesis, and challenged the mainstream gene mutation theory at that time. However, whether aneuploidy causes tumorigenesis or is the consequence of it remains debated, aneuploidy has emerged as new regulators for cancer biology. Figure 1 The figure illustrates defects in several processes involving chromosomes, spindle microtubules and centrosome targets, which, in addition to abnormal cytokinesis, may also lead to uneven distribution of chromosomes during mitosis, leading to aneuploidy. Because aneuploidy represents the digital imbalance of chromosomes, it can be reasonably expected that aneuploidy is caused by chromosome segregation errors in the process of cell division. Aneuploids include whole chromosomes, chromosome arms, and local chromosomes (this article focuses on the introduction of whole chromosomes), which are mainly caused by the misseparation of chromosomes in the cell cycle caused by mitotic checkpoint defects. 6 Aneuploidy can also be found in tissue cells of healthy people, and that aneuploidy contributes to the development and selection of malignant clones and promotes the phenotypic development of tumor progression (Figure 1). 7 About 60% of NSCLC patients are aneuploid, and aneuploid NSCLC is one of the most common tumors. 8 Sundaresan et al 9 observed the phenomenon of somatic chromosome deletions in lung squamous cell precancerous lesions as early as 1992. Subsequent studies found that the incidence of aneuploidy in small cell lung cancer was 77.8%, which was higher than that in any other histological type of lung cancer. 10 Studying the involvement of aneuploidy in cancer may provide new ideas for future research on cancer treatment. Tumorigenesis and aneuploidy are known to be closely related, but their precise relationship remains unclear. In this paper, we review the results of a large number of clinical studies on NSCLC published since 2000, which discuss the -Abstract Truncated-

67 Cancer aneuploidy is associated with a distinct tumor immune microenvironment and impacts outcomes to immune checkpoint inhibition in nonsquamous non-small cell lung cancer

Abstract 620: Associations of Genomic Alteration, Tumor Mutational Burden with PD-L1 Expression and Response to Immune Checkpoint Inhibitors in Chinese Lung Patients

Abstract 1243: Identification of aneuploidy biomarkers associated with response to first-line treatment of metastatic pancreatic cancer

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

Abstract 6668: Immune infiltrate co-occurrence and neoantigen similarity are prognostic factors in early stage NSCLC

Abstract NG03: Functional and computational approaches to uncover selection advantages of cancer aneuploidy

PD-L1+ aneuploid circulating tumor endothelial cells (CTECs) exhibit resistance to the checkpoint blockade immunotherapy in advanced NSCLC patients.

The prognosis and metabolite changes of NSCLC patients receiving first-line immunotherapy combined chemotherapy in different M1c categories according to 9th edition of TNM classification

Mutational burden and chromosomal aneuploidy synergistically predict survival from radiotherapy in non-small cell lung cancer

Clinical Applications of Aneuploidies in Evolution of NSCLC Patients: Current Status and Application Prospect

Abstract CT026: The effect of intrinsic subtype on inhibition of tumor growth by anastrozole vs. fulvestrant vs. the combination: Results from the Alliance neoadjuvant endocrine therapy (NET) ALTERNATE trial

Abstract 3634: Copy number alterations in chromosome 19 genes associate with reduced immune infiltrate and adverse outcomes in lung cancer

Abstract A012: Stratifying immune subtypes in real-world HNSCC cohort to identify those with better outcomes to standard treatment regimens

Integrated bulk and single-cell RNA sequencing identifies an aneuploidy-based gene signature to predict sensitivity of lung adenocarcinoma to traditional chemotherapy drugs and patients' prognosis

Advanced Non-Small Cell Lung Cancer Patients with Low Tumor Mutation Burden Might Derive Benefit from Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Deathligand 1 (PD-L1) Blockade

Abstract 4393: Tumor volumetric analysis to correlate disease burden with response to dual immune checkpoint blockade in metastatic NSCLC

Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer

Circulating tumor cells with increasing aneuploidy predict inferior prognosis and therapeutic resistance in small cell lung cancer

Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy

Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC.

Advanced Non–Small Cell Lung Cancer Patients with Low Tumor Mutation Burden Might Derive Benefit from Immunotherapy